GE and CBMG collaborated to co-develop CAR-T and Stem Cell Manufacturing

GE Healthcare and CBMG (Cellular Biomedicine Group) collaborated to co-develop certain industrial control processes in CAR-T (Chimeric Antigen Receptor T-cell) and stem-cell manufacturing.

The companies will establish a joint laboratory within CBMG’s Zhangjiang GMP-facility and dedicate it to the joint research and development of a functionally integrated, as well as automated immunotherapy cell preparation system.

The automated CAR-T and stem-cell manufacturing capabilities are set to build upon the accreditation of GMP facilities of CBMG in Shanghai, Wuxi and Beijing. With an expanded Wuxi, and Beijing GMP-facilities, CBMG’s new Zhangjiang facility will have a combined 70,000ft² for development and production.

GE Healthcare Life Sciences Greater China general manager, Li Qing said that Cell therapy as an industry continues to refine and evolve in China, with vast potential to change the ways various diseases are treated.